Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)
Authors
Keywords
-
Journal
MEDIATORS OF INFLAMMATION
Volume 2010, Issue -, Pages 1-11
Publisher
Hindawi Limited
Online
2010-06-21
DOI
10.1155/2010/592760
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibition of CD26/Dipeptidyl Peptidase IV Enhances CCL11/Eotaxin-Mediated Recruitment of Eosinophils In Vivo
- (2014) U. Forssmann et al. JOURNAL OF IMMUNOLOGY
- Incretin-based Therapies for Type 2 Diabetes
- (2012) Christopher H.S. McIntosh Canadian Journal of Diabetes
- Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?
- (2009) M. Nauck et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Reactive species and diabetes: counteracting oxidative stress to improve health
- (2009) Patricia Pérez-Matute et al. CURRENT OPINION IN PHARMACOLOGY
- Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes: Interactions With Metformin
- (2009) A. V. Matveyenko et al. DIABETES
- Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
- (2009) J. S. Nachnani et al. DIABETOLOGIA
- Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes
- (2009) James Mu et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials
- (2009) E. Mannucci et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
- (2009) M. Monami et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors
- (2009) E.J. Verspohl PHARMACOLOGY & THERAPEUTICS
- Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies
- (2008) A. Penfornis et al. DIABETES & METABOLISM
- Islet Inflammation in Type 2 Diabetes: From metabolic stress to therapy
- (2008) M. Y. Donath et al. DIABETES CARE
- Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes
- (2008) Kenji Nonaka et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice
- (2008) Yusuke Moritoh et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Glucotoxicity and pancreatic proteomics
- (2008) Yannick Brunner et al. Journal of Proteomics
- Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
- (2008) Peter Gæde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exercise training decreases proinflammatory profile in Zucker diabetic (type 2) fatty rats
- (2008) E. Teixeira de Lemos et al. NUTRITION
- Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk
- (2008) E. Mannucci et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now